Evonik invests into technical upgrade of its European methionine Verbund

Evonik is continuing to optimize its global production setup for MetAMINO® (DL-methionine) with a technical upgrade of its European methionine Verbund Antwerp (Belgium)/Wesseling (Germany). The low double-digit million euro investment requires a partial shutdown of these facilities for 8-10 weeks in the period May to July 2025. All existing contracts and supply agreements will be honored.

“We are constantly working to further increase the process efficiency, reliability and sustainability of our three global methionine production hubs. This is how we remain competitive and ensure highest possible supply security for our customers,” said Dr. Dirk Hoehler, head of the amino acids business of Evonik’s Animal Nutrition business line.

Measures to increase process efficiency and reliability include a new process control system and a new bagging station. Various technical improvements will contribute to reduce nitrogen, sulfur, and CO2 emissions. Hoehler: “To reduce our ecological footprint is an ongoing, strong motivation for us. We are committed to the strictest European sustainability requirements.”

Evonik is the only global player in methionine that serves growing global feed markets from three world-scale production hubs in three regions of the world: Antwerp/Wesseling, Mobile (Alabama, USA), and Singapore. In the last three years, Evonik has invested over €200 million in expanding its methionine facilities in Singapore and in the backward integration of methionine production in Mobile.

MetAMINO® is used in livestock production to feed animals healthily, efficiently, and sustainably. With its science-based approach, the Animal Nutrition business line of Evonik develops products, services and system solutions that help supply a growing world population with healthy, high-quality and affordable animal protein.

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.2 billion and an operating profit (adjusted EBITDA) of €2.1 billion in 2024. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 32,000 employees work together for a common purpose: We want to improve life today and tomorrow.